WO2008152624A2 - Formulation stimulante à base de plantes médicinales - Google Patents
Formulation stimulante à base de plantes médicinales Download PDFInfo
- Publication number
- WO2008152624A2 WO2008152624A2 PCT/IL2008/000767 IL2008000767W WO2008152624A2 WO 2008152624 A2 WO2008152624 A2 WO 2008152624A2 IL 2008000767 W IL2008000767 W IL 2008000767W WO 2008152624 A2 WO2008152624 A2 WO 2008152624A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation according
- formulation
- cichorium
- intypus
- ratio
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000009472 formulation Methods 0.000 title claims abstract description 43
- 241000196324 Embryophyta Species 0.000 claims abstract description 24
- 235000014755 Eruca sativa Nutrition 0.000 claims abstract description 18
- 235000015243 ice cream Nutrition 0.000 claims abstract description 18
- 241000723343 Cichorium Species 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 230000001256 tonic effect Effects 0.000 claims abstract description 8
- 241001149093 Eruca vesicaria subsp. sativa Species 0.000 claims abstract 12
- 239000003814 drug Substances 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 5
- 230000036626 alertness Effects 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 235000013618 yogurt Nutrition 0.000 claims 2
- 244000269722 Thea sinensis Species 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 235000015897 energy drink Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 235000014214 soft drink Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract description 25
- 239000000284 extract Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 10
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000008030 elimination Effects 0.000 abstract description 5
- 238000003379 elimination reaction Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000000419 plant extract Substances 0.000 abstract description 4
- 238000006213 oxygenation reaction Methods 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 239000012674 herbal formulation Substances 0.000 abstract description 2
- 230000001568 sexual effect Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 244000298479 Cichorium intybus Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 235000007542 Cichorium intybus Nutrition 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 9
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 9
- 244000024675 Eruca sativa Species 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 3
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- -1 Stearoyl Vanillylamide Chemical compound 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003048 aphrodisiac agent Substances 0.000 description 2
- 230000002509 aphrodisiac effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- MUROMQNYCWNWFJ-UHFFFAOYSA-N 3-Ketone-9beta-Hydroxy-4beta, 11alpha, 13, 15-tetrahydrozaluzanin C Natural products C1C(O)C(=C)C2CC(=O)C(C)C2C2OC(=O)C(C)C21 MUROMQNYCWNWFJ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 231100000911 LD50 test Toxicity 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical class COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- SKNVIAFTENCNGB-UHFFFAOYSA-N dehydroleucodine Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CC(=O)C2=C1C SKNVIAFTENCNGB-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- GKUMMDFLKGFCKH-AHMUMSBHSA-N glucoerucin Chemical compound CSCCCC\C(=N\OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GKUMMDFLKGFCKH-AHMUMSBHSA-N 0.000 description 1
- DJOJPSRRKWYLCC-URYVQPGZSA-N glucoerucin Natural products CSCCCCC(=N/S(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DJOJPSRRKWYLCC-URYVQPGZSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229930015714 guaianolide Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
Definitions
- the present invention relates to an herbal formulation comprising Eruca Sativa and Cichorium Intypus.
- the formulation in preferred embodiments or combination, has effect or synergetic effect in energizing human body energy and tonic.
- This invention is based on original research made by Dr Omar said and Khaled Khalil from Antaki center For Herbal Medicine Ltd.
- This formulation contains active fractions of two plant extracts (Eruca Sativa & Cichorium Intypus) used as main principles for novel food products or supplement, drinks, and Ice cream in a final concentration of 5% of active ingredients per Kg which is equivalent to 250 gram of fresh plants.
- Extracts Eruca Sativa & Cichorium Intypus
- Ice cream in a final concentration of 5% of active ingredients per Kg which is equivalent to 250 gram of fresh plants.
- Our extensive research that used Ice cream as an example have confirmed that these specific fractions possess remarkable antioxidant, blood lactate elimination, liver and sexual tonic, cell oxygenation, body endurance and adaptogenic activities.
- the plants extract is completely safe.
- the mixture is a powerful general tonic, which enhances bodily energy, reduces physical exhaustion and fatigue and Increases endurance and mental performance due to:
- a. Powerful hepatic stimulant increases blood lactate elimination, acts on liver glycogen and promotes immediate energizing.
- Natural effective antidote e. Improves antioxidant activity.
- LDH release assay was performed. It was reported that LDH is released from the cells when plasma membrane integrity is destroyed by necrotic rupture.
- the integrity of the plasma membrane was determined by measuring LDH activity released into the culture medium. LDH activity was monitored following the oxidation of NADH as the decrease in absorbance at 334 nm. The reaction was carried out in a potassium phosphate buffer (40 niM K 2 HPO 4 , 10 mM KH 2 PO 4 , pH 7.5), containing 0.24 mM NADH and 0.62 mM pyruvate. The percentage of LDH released was defined as the ratio of LDH activity in the supernatant to the sum of LDH amount released plus the activity measured in the cell lysate. Human Fibroblast cells were incubated with different amounts of extract for 24h, 48h and 72h. In the end of the incubation time, the LDH activity was measured in the medium.
- LD50 test on rats showed extreme safe results: 24 gm/kg (the test was carried out in the department of pharmacology, Technion - Haifa, Israel). This value indicates high level of safety.
- Energy Ice cream extract acts as a powerful natural anti-oxidant and is able to suppress the damaging affects of oxidation on liver cell membranes. This helps to counteract cellular decay and protects against different diseases. This test was carried out at Antaki Ltd. Research and Development facility.
- Lipid peroxidation The extent of lipid peroxidation was measured using a technique based on a thiobarbituric acid reactive substances (TBARS) assay that detects malondialdehyde (MDA) 5 an end-product of peroxidative decomposition of polyeonic fatty acids in in vitro systems.
- TBARS thiobarbituric acid reactive substances
- MDA malondialdehyde
- ROS generating systems - ROS was generated using FeSO 4 (0.1-1 mM) as described by Draper et al.
- the tetrazolium dye, MTT is widely used to assess the viability and/or the metabolic state of cells (1).
- This colorimetric assay is based on the conversion of the yellow tetrazolium bromide (MTT) to the red formazan derivative by mitochondrial succinate dehydrogenase in viable cells. Twenty-four hours after cell seeding, cells were incubated with varying concentrations of the plant extracts for 24 h at 37°C. Following removal of the plant extracts from each well, cells were washed in phosphate-buffered saline. The cells were then incubated in serum-free DMEM to which MTT (0.5 mg ml "1 ) will added to each well (100 ⁇ l), and incubated for a further 4 h.
- MTT yellow tetrazolium bromide
- Lactate is produced, mainly, in muscle cells during exercise, and diffuses out into the blood where it can be measured. At rest, the blood lactate concentration is low at about 0.8- 2.5mmol/L, but can be raised as the intensity of exercise increases and could rise to 20 times higher than normal rest levels leading to exhausting (extreme fatigue) feeling. Accumulation occurs when the supply of oxygen to the cells is limited because the muscle cells are working extensively. During everyday activities, the oxygen supply to the muscle cells is sufficient to enable the cells to utilize energy; however, when there is a sudden need for excessive muscular effort, the lactic acid mechanism is activated to enable activity to continue even though the oxygen supply is insufficient. This is known as the anaerobic phase of exercise in contrast to the aerobic phase which implies an adequate oxygen supply to the muscle cells.
- Lactate threshold also called anaerobic threshold is the point where lactate begins to accumulate in the bloodstream during exercise at level of about 3.5-4.0mmol/L in healthy peoples. Beyond these lactate levels fatigue will occur. Consequent training and sporting could create tolerance to high lactate levels (increasing lactate threshold).
- Forced swimming test is an acceptable scientific tool used for determining maximum swimming time in mice as a criterion of physical work capacity.
- the mice were forced to swim at a flow rate of 8 L/min, to until exhaustion, and swimming capacity was measured. Mice were considered as fatigued when they failed to rise to the surface of the water to breathe within a 7 seconds period. A period of longer than 7 seconds frequently resulted in drowning. The total swimming time until exhaustion was used as the index of swimming capacity.
- Serum lactate analysis Blood samples were taken from the tail during the 10th, 20th and 30th minutes of exercise, as described by Matsumoto et al (2). Blood samples for lactate determination were immediately deproteinized in perchloric acid (0.8 N) and centrifuged, and the serum L-lactic acid concentration was determined by commercial kit (1, 2).
- the graph in Figure 7 indicates that 7 days pre feeding with Energy Ice cream extract (5mg/kg), have significantly reduced the mice blood lactate levels compared with the placebo and caffeine groups. These remarkable results can be explained by the powerful liver stimulant activity of Energy Ice cream extract which may lead to high efficient elimination of lactate from the bloodstream, and breakdown of liver glycogen. 1. Kyung-Mi Kim, Teruo Kawada, Kengo Ishihara, Kazuo Inoue, and Tohm Fushiki, swimming Capacity of Mice Is Increased by Oral Administration of a Nonpungent Capsaicin Analog, Stearoyl Vanillylamide, The Journal of Nutrition Vol. 128 No. 11 November 1998, pp. 1978-1983.
- Lactate as a by-product of the anaerobic/glycolytic energy pathway can be measured by sampling blood.
- the accumulation of blood lactate in response to incremental loading is traditionally thought to reflect the levels of lactate that are produced in muscles (1-4).
- Rocket was always considered to be a potent aphrodisiac
- Eruca sativa is known generally as a food, in which the leaves are eaten as part of salads. It has been known as a garden vegetable since Bible Times, and there are many records of its household usage from the Hellenistic period onwardsl. It has collected the major uses throughout history and classifies them. These uses are: for eye infections (antibacterial action), increasing fertility and sperm production, as deodorant when eaten internally or when sprinkling ground seeds under the arms, as an aid to digestion and kidney function. Maimonedes and Ibn Wahsiyya are quoted as stating that the ground seeds when mixed in a cream and spread on the face can be used for acne. There is a classic review of the uses of this plant which illustrates its wide application in traditional medicine2.
- Eruca sativa has a weak antimicrobial effects. It has been tested against a range of bacteria, yeasts, crustaceans and insect larvae and has been found to be active at high concentrations3,4.
- the Eruca sativa extract was found to possess a potent antioxidant effect, with a large amount of polyphenols and a high reducing ability, glucoerucin and flavonoids are the major antioxidants present in it.
- ROS reactive oxygen species
- RNS reactive nitrogen species
- Wild chicory (Cichorium intybus) - Powerful hepatic stimulant, general and brain tonic, appetizer, hypoglycaemic, increases bile secretion, hepato protective, acts on liver glycogen and promotes digestion;
- Chicory is a well-known food and traditional remedy. It is mentioned in most of the major herb books of the Western world, such as Grieves, etc. The plant is a perennial, with a large taproot like that of dandelion. It is used much as dandelion for health, including the making of a healthier alternative to coffee, and as a preventive and curative remedy. It has a similar bitter taste. It is cultivated widely throughout Europe for use in salads.
- the root contains inulin and oligofructose polysaccharides(10, which are typical to the plant and of interest as a source of medicinally important probiotic fiber.
- the plant as a whole contains several guaianolide sesquiterpene lactonesll. Similar compounds in other plants such as feverfew are known to have anti-inflammatory activity.
- Chicory is used much like dandelion in European herbal medicine. That is, it is helpful in cleaning the body and supporting the liver and also in stimulating the eliminative processes both via the intestine and the kidneys(12). It is a warming and tonifying plant, and the fresh root is used traditionally in chest problems and cold conditions. The plant is classically used in cold countries as part of soup to ward off colds and flu. Professional herbalists also use the plant as part of mixtures for the treatment of dry coughs, chest pain and bronchial problemsl3. Arabic traditional healers today regard chicory as part of a combined treatment of metabolic problems, and a medicine to cleanse the body, and treat colds and flu. Research
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention porte sur une formulation à base de plantes médicinales comprenant Eruca Sativa et Cichorium Intypus. Dans une combinaison ou des modes de réalisation préférés, la formulation a pour effet ou effet synergique de stimuler et de tonifier le corps humain. Les principes actifs de la formulation sont constitués de fractions actives de deux extraits végétaux (Eruca Sativa & Cichorium Intypus) utilisés dans de nouveaux produits alimentaires ou complément alimentaire, boissons et crème glacée dans une concentration finale de 5 % d'ingrédients actifs par kg, ce qui est équivalent à 250 grammes de plante fraîche. Une recherche approfondie prenant la crème glacée comme exemple a confirmé que ces fractions spécifiques possèdent de remarquables effets anti-oxydants, éliminateurs du lactate sanguin, oxygénants des cellules, améliorants de l'endurance physique et adaptogènes, et sont considérés comme tonifiants hépatiques et sexuels. Ces extraits végétaux ne présentent aucun danger.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93161207P | 2007-06-15 | 2007-06-15 | |
| US60/931,612 | 2007-06-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2008152624A2 true WO2008152624A2 (fr) | 2008-12-18 |
| WO2008152624A3 WO2008152624A3 (fr) | 2009-02-19 |
| WO2008152624A4 WO2008152624A4 (fr) | 2009-05-28 |
Family
ID=40130276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL2008/000767 WO2008152624A2 (fr) | 2007-06-15 | 2008-06-05 | Formulation stimulante à base de plantes médicinales |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008152624A2 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9709082D0 (en) * | 1997-05-06 | 1997-06-25 | Ciba Geigy Ag | Organic compositions |
| US20070122492A1 (en) * | 2004-11-18 | 2007-05-31 | Stephen Behr | Plant extracts and dermatological uses thereof |
| EP1550451A1 (fr) * | 2003-12-29 | 2005-07-06 | Boehringer Ingelheim International GmbH | Traitement des insuffisances veineuses chroniques à l'aide d'un extrait de feuilles de vigne rouge et d'un diuretique |
| US20060110519A1 (en) * | 2004-11-19 | 2006-05-25 | Atkins Nutritionals, Inc. | Low-glycemic alcoholic beverages and methods for making same |
| US8962058B2 (en) * | 2005-11-23 | 2015-02-24 | The Coca-Cola Company | High-potency sweetener composition with antioxidant and compositions sweetened therewith |
-
2008
- 2008-06-05 WO PCT/IL2008/000767 patent/WO2008152624A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008152624A4 (fr) | 2009-05-28 |
| WO2008152624A3 (fr) | 2009-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102076459B1 (ko) | 갈색거저리 효소처리물을 함유하는 회복기 환자 또는 노약자의 근육량 증강 및 원기회복용 조성물 | |
| US11122832B2 (en) | Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise | |
| MXPA06012501A (es) | Composicion nutricional que promueve la perdida de peso, quema calorias, aumenta la termogenesis, sustenta el metabolismo de la energia y/o suprime el apetito. | |
| US8206764B2 (en) | Black soybean hull extract, method for obtaining, and use thereof | |
| US20030119913A1 (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof | |
| KR20090036579A (ko) | 손상된 신경전달과 관련된 질환의 치료를 위한 약품 | |
| WO1999051252A1 (fr) | Procede et composition servant a ameliorer la circulation sanguine | |
| KR100448260B1 (ko) | 체중조절용 특수영양식품의 제조방법 | |
| KR20190030642A (ko) | 뇌 활성 증진용 조성물 | |
| US20200100534A1 (en) | Method of reducing weight regain in mammals | |
| US20080139657A1 (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof | |
| Kelishadi | Cacao to cocoa to chocolate: healthy food? | |
| ES2747932T3 (es) | Uso de fitoecdisonas en la preparación de una composición para actuar sobre el síndrome metabólico | |
| AU2002305132B2 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| WO2006021930A2 (fr) | Composition aux herbes aphrodisiaques pour les femmes, comprimes ou capsules comprenant cette composition et procede d'auto-administration de ladite composition | |
| JP2003061613A (ja) | 肝臓保護用健康食品組成物（Ｈｅａｌｔｈｙｆｏｏｄｃｏｍｐｏｓｉｔｉｏｎｆｏｒｐｒｏｔｅｃｔｉｎｇｈｅｐａｔｉｃ） | |
| WO2008152624A2 (fr) | Formulation stimulante à base de plantes médicinales | |
| CA2606732C (fr) | Composition destinee a prevenir et a traiter la xylostomiase | |
| US20240307478A1 (en) | Phosphodiesterase 5 inhibitor | |
| Jurcău et al. | Influence of Lepidium meyenii on stress induced by walking on a treadmill. | |
| Jain et al. | Hawthorn–Lysine | |
| RU2635373C1 (ru) | Биологически активная добавка для повышения общей работоспособности | |
| Simons | The Healing Power of Plants: Medical Plants from Abuta and Acerola to Yohimbe and Yucca: a Practical Selection | |
| RU2659172C1 (ru) | Комбинация двух криопротекторных сборов для адаптации человека к охлаждающему микроклимату | |
| KR20170122612A (ko) | 호로파 추출물 및 페룰산을 함유하는 스포츠용 조성물 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08763525 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08763525 Country of ref document: EP Kind code of ref document: A2 |